Alternatively, in prior work with the T2D BTBR-Ob mouse model, we find acute treatment with EP3 agonists noncompetitively antagonize agonists of the GLP1R, limiting their maximal potentiating effect on cAMP production and GSIS (22). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.